Pliant Therapeutics【PLRX】銘柄情報

Pliant Therapeutics Inc (PLRX) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

1.15

( - )

買値

1.13

売値

1.28

出来高

0.00 日の範囲 0.00

1.09 52 週間の範囲 1.95

時価総額

71.202M

前日終値

1.15

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 552,636

発行済株式数

61,914,664

配当利回り

PER

-0.65

1 株当たり利益 (EPS)

-1.83

歳入

純利益

-113.22M

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that i... Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

pliantrx.com

本社

South San Francisco, United States

設立

2026

Pliant Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker PLRX. The last closing price for Pliant Therapeutics was US$1.15. Over the last year, Pliant Therapeutics shares have traded in a share price range of US$ 1.09 to US$ 1.95.

Pliant Therapeutics currently has 61,914,664 shares in issue. The market capitalisation of Pliant Therapeutics is US$71.20 million. Pliant Therapeutics has a price to earnings ratio (PE ratio) of -0.65.

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095Oral presentation at...

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a...

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.05	-4.16666666667	1.2	1.22	1.13	693504	1.16842753	CS
4	-0.05	-4.16666666667	1.2	1.275	1.13	549552	1.18874656	CS
12	-0.16	-12.213740458	1.31	1.38	1.13	501552	1.24130656	CS
26	-0.13	-10.15625	1.28	1.435	1.09	691340	1.25037725	CS
52	-0.5	-30.303030303	1.65	1.95	1.09	917141	1.39457799	CS
156	-21.55	-94.9339207048	22.7	24.74	1.09	860479	6.36132969	CS
260	-30.43	-96.3584547182	31.58	36.64	1.09	744469	11.1862626	CS